2 Outstanding Dividend Stocks That Are Too Cheap to Ignore

The article highlights Zoetis and Nomad Foods as compellingly undervalued dividend stocks, presenting attractive opportunities for institutional investors. Zoetis, the global leader in animal healthcare, has experienced a significant stock decline due to pandemic-related growth normalization and initial drug disappointments, yet it boasts a 22% return on invested capital and a decade of 19% annual dividend growth, now trading at a historically low 20x earnings. Concurrently, Nomad Foods, Europe's leading frozen food provider, trades at its lowest-ever 7x EV/EBITDA multiple following a 62% stock drop, attributed partly to temporary weather disruptions, while management actively repurchases shares and projects 15% annual free cash flow growth, supporting a 5.7% dividend yield. Both companies are highlighted as strong "buy-the-dip" candidates, underpinned by robust market positions and shareholder-friendly capital allocation.

Analysis

Zoetis (ZTS) presents a compelling value proposition, trading at a "once-in-a-decade" valuation of 20 times earnings after losing half its market value since 2022. Despite being the global leader in animal healthcare with 17 blockbuster products, the company has faced challenges from normalizing pandemic-driven pet adoption trends and initial disappointments with its monoclonal antibody (mAb) drugs.

However, Zoetis's innovation engine remains robust, with longer-lasting versions of its OA mAbs in development, which could significantly improve adoption. Its livestock unit provides a stable counterbalance, benefiting from rising protein demand, while the company maintains an elite 22% Return on Invested Capital (ROIC). This strong profitability supports a 19% annual dividend growth over the last decade, with a current 1.7% yield and a conservative 34% payout ratio.

Nomad Foods (NOMD), Europe's leading frozen food provider, is trading at an "ubercheap" 7x EV/EBITDA, a 62% decline from its 2021 peak. Recent sales and adjusted earnings declines were attributed to industry-wide weather disruptions, not company-specific issues, and its focus on healthier protein and vegetable options positions it for long-term tailwinds.

Management projects 15% annual free cash flow growth through 2028 and actively repurchases shares, reducing the count by 4% annually over five years. The company also initiated a new 5.7% dividend yield with a 46% payout ratio, further reinforced by a $1 million insider purchase by the CFO, signaling strong confidence in its deeply discounted valuation.

Key Decisions for Investors

• Consider initiating or increasing positions in Zoetis (ZTS) for long-term dividend growth, leveraging its market leadership, strong innovation pipeline, and historically low valuation despite recent operational challenges.
• Evaluate Nomad Foods (NOMD) for deep value and capital appreciation, given its dominant European market position, aggressive share repurchases, new dividend initiation, and management's confident outlook on free cash flow growth.
• Monitor the market adoption of Zoetis's next-generation mAb treatments and Nomad Foods' continued success in expanding its healthier food offerings to validate growth trajectories.